Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis
| Autor: | Edurne Ruiz de Gopegui-Ruiz, Iñigo Pomposo-Gaztelu, Gregorio Catalán-Uribarrena, Gaizka Bilbao-Barandica, Manuel Canales-Llantada, Guillermo Carbayo-Lozano, Lara Galbarriatu-Gutiérrez, José Undabeitia-Huertas, Alfonso Igartua-Azkune, Jon Aurrecoechea-Obieta |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Cohort Studies Glioma Antineoplastic Combined Chemotherapy Protocols medicine Temozolomide Humans Prospective Studies Karnofsky Performance Status Prospective cohort study Antineoplastic Agents Alkylating Craniotomy Retrospective Studies Carmustine Intention-to-treat analysis business.industry Brain Neoplasms Middle Aged medicine.disease Prognosis Surgery Dacarbazine Survival Rate Chemotherapy Adjuvant Cohort Female Radiotherapy Adjuvant Neurology (clinical) Neurosurgery Neoplasm Grading business medicine.drug Follow-Up Studies |
| Zdroj: | Acta neurochirurgica. 154(2) |
| ISSN: | 0942-0940 |
| Popis: | Patients with high-grade glioma can be treated with carmustine wafers or following the Stupp protocol. As far as we are aware, no scientific evidence has been published comparing the two treatments. The primary objective of this study was to analyse the survival of groups of patients with each of these treatment modalities. The secondary objective was to assess the influence of the usual prognostic factors on the patients in our hospital. A prospective cohort of 110 patients with single, supratentorial high-grade glioma treated by craniotomy and tumour resection was retrospectively studied. Half of the patients had carmustine wafers placed during this operation while the others (55) did not, the latter group receiving first-line systemic chemotherapy on an intention-to-treat basis. Patients treated with carmustine wafers had a median survival of 13.414 months compared with 11.047 in the group without implants (p = 0.856). For the overall cohort of patients, the following factors were found to influence survival: age (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink